Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr, MacFarland
View:
Post by jmm1228 on Oct 04, 2022 9:39pm

Dr, MacFarland

She is, I think, the patent holder and scientist who  granted the license of her discovery to TLT. 

I wonder what her expectations were when she did this and how she views the activity on her behalf since, and what her expectations were then and how she views the fulfillment of them to date.

It is pretty much a given that she has delivered a potentially brilliant treatment in the cancer realm.

The implementation of her brilliance does not parallel her discovery.

 I expect she would welcome a better market pathmaker after the near term approval process confirms the efficacy of her brilliant work.

This matter has a need for excellence of leadership as the "moment critique" must be deftly handled.

Who is going to crack the whip?
Comment by 2b7f6fab on Oct 05, 2022 8:57am
Correct me please if I have it wrong.  But my understanding is that Dr MacFarland tried marketing her invention to big pharma but there were no takers.  Only RW saw the potential.
Comment by Yajne on Oct 06, 2022 9:59pm
now 2b7fb6fab, that sounds like something worth 'fact checking', although I doubt that the public domain contains the info necessary to do the fact check on your assertion...
Comment by gojotv! on Oct 07, 2022 2:09am
This post has been removed in accordance with Community Policy
Comment by gojotv! on Oct 07, 2022 2:13am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250